chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Left shoulder still sore, rash near injection site, head ache, fatigue, and was very cold. Had to leave early from work and go home. Wasnt able to get home until 1430 due to train schedule. Took a shower, and went to sleep. Woke up about 1930 covered in sweat, and still tired. Went back to sleep until 0200, and had to get out of bed because I was cold. Took another shower, and changed into dry clothes. Slept until 0630, but did not feel well. Headache was worse, but I wasnt cold anymore. Slept through most of day, 16 Oct, and was able to eat a little for breakfast and lunch, and drank water and orange juice. Did not eat dinner on 15 or 16 Oct. Went to work on 17 Oct.
Extreme pain in left arm radiating throughout entire body, severe trembling, chills, fever, nausea, shortness of breath  Beginning at 11:30PM continuing throughout the night  - without sleep.  Resulting next day  (Monday 10/11) in extreme fatigue, continued trembling, fever, chills.  Still in wakened state but  SLOWLY recovering on third day 10/12/2021.  Sense of taste has dwindled.  Same reaction at second injection - though not as severe.  Was strongly encouraged to receive booster against MY better judgement.
This case was reported by a physician and described an adult subject of unspecified gender who did not respond to vaccination with hepatitis B vaccine recombinant (Engerix B). On an unspecified date before 9/23/2005, the subject completed the first series of Engerix B. At an unspecified time following the completion of the first series of Engerix B, on an unspecified date before 9/23/2005, a hepatitis B surface antibody titer was negative. On an unspecified date before 9/23/2005, the second series of Engerix B was completed. At an unspecified time following receipt of the 6 dose of Engerix B, on an unspecified date on or before 9/23/2005, a hepatitis B surface antibody titer was negative.
That day...chills, fatigue, arm soreness The next day...arm red, swollen, hot, sore A week later...arm red, hot, achy
Pain at injection and local induration.  Seen in the ER and treated w/ course of abx for presumed cellulitis.  Seen by doctor after ER and given course of Antihistamine, Steroids, and H2 Blocker.
Information has been received from a licensed practical nurse referring to multiple unspecified patients of unknown age and gender. Information regarding concomitant medication, medical history and drug reactions/allergies was not reported. On unknown dates, the patients might have received doses of improperly stored PNEUMOVAX 23 (single-dose vial) (lot # L027732 with expiration date 23-FEB-2017; dose and route were not reported). The vaccine was exposed to 31 Fahrenheit for 40 minutes. There was no prior excursion. Data logger was unknown. No adverse effects were reported. At the reporting time, the reporter did not sure if the vaccine was administered. This is one of several reports received from the same reporter. Additional has been requested.
Pt had visual disturbance, felt warm & throat pain. Pt was given BENADRYL 25 mg IM.
pt recv vax 17OCT94 & devel periorbital cellulitis & was hospitalized 12FEB94; H. influenzae (type unk) was isolated; titer levels measured; titer was 0.55 ug/ml; IGG, IGA & IGM were nl; recovery status unk23JUN95-mfr f/u state pt recovered
No adverse event; Excess pool from multiple vials/patient received pooled vaccine from the Moderna bivalent vaccine.; Patients received pooled vaccine from the Moderna bivalent vaccine.; This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT PREPARATION ERROR (Excess pool from multiple vials/patient received pooled vaccine from the Moderna bivalent vaccine.), PRODUCT ADMINISTRATION ERROR (Patients received pooled vaccine from the Moderna bivalent vaccine.) and NO ADVERSE EVENT (No adverse event) in a 27-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 030G22B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 07-Oct-2022, the patient received fourth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .5 milliliter. On 07-Oct-2022, the patient experienced PRODUCT PREPARATION ERROR (Excess pool from multiple vials/patient received pooled vaccine from the Moderna bivalent vaccine.) and PRODUCT ADMINISTRATION ERROR (Patients received pooled vaccine from the Moderna bivalent vaccine.). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT PREPARATION ERROR (Excess pool from multiple vials/patient received pooled vaccine from the Moderna bivalent vaccine.), PRODUCT ADMINISTRATION ERROR (Patients received pooled vaccine from the Moderna bivalent vaccine.) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for PRODUCT PREPARATION ERROR (Excess pool from multiple vials/patient received pooled vaccine from the Moderna bivalent vaccine.) and PRODUCT ADMINISTRATION ERROR (Patients received pooled vaccine from the Moderna bivalent vaccine.).    No concomitant medications were reported.   It was reported that patient that received a Moderna bivalent vaccine from excess pool from multiple vials.  Patient took Moderna first  dose on 07-Jun-2021, Lot Number 036C21A, with an expiration date of 01-Nov-2021. Patient took Moderna second dose on 06-Jul-2021, Lot Number 008C21A, with an expiration date of 13-Oct-2021. Patient took Moderna first booster of 0.25 mL on 11-Mar-2022, Lot number 066K21A, with an expiration date of 07-Jul-2022.  No treatment medication was provided.   This case was linked to US-MODERNATX, INC.-MOD-2022-658197, US-MODERNATX, INC.-MOD-2022-658264 (Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 12-Oct-2022: Live follow-up received included patient demographics, suspect product details and narrative updated. On 12-Oct-2022: Live follow-up received and patient's age group added.; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-658197:Patient 2 (bivalent) US-MODERNATX, INC.-MOD-2022-658264:Patient 2 (dose 2)
Stevens Johnson Syndrome; Stevens Johnson Syndrome; This is a spontaneous report from a contactable consumer (patient). A 49-50-year-old female patient received pneumococcal 13-val conj vac (dipht crm197 protein) (PNEUMOCOCCAL 13-VAL CONJ VAC (DIPHT CRM197 PROTEIN)) (reported as "baby" pneumonia shot), via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as single dose for immunisation; diphtheria vaccine toxoid, pertussis vaccine acellular, tetanus vaccine toxoid (TDAP), route of administration, start and stop date, batch/lot number and dose were not reported for immunisation; influenza vaccine (FLU VACCINE), route of administration, start and stop date, batch/lot number and dose were not reported for immunisation. Medical history included ongoing alopecia from age 13, stevens-johnson syndrome from an unknown date in her late 20s from a tar treatment for alopecia. The patient's concomitant medications were not reported. The patient was around 49-50 years old and she received 3 vaccines- the flu shot, a "baby" pneumonia shot, (she states she can't take an adult pneumonia shot), and at TDaP shot. She received the vaccinations on a Tuesday and develop SJS on Thursday. She was 49-50 years old at the time. The outcome of the events was unknown.  Information about lot/batch number has been requested.
Systemic: Chills-Mild, Systemic: Dizziness / Lightheadness-Medium, Systemic: Fainting / Unresponsive-Severe, Systemic: purfuse sweating, lose of sight left eye, dizziness, nausea-Severe, Systemic: Nausea-Mild, Systemic: Shakiness-Medium, Systemic: Visual Changes/Disturbances-Severe, Additional Details: Patient began to fell better about 5 minutes after epinephrine was administered. EMS was called but did not transport.
Small bowel obstruction - Patient was kept  and given IV fluids. Surgery was consulted and patient had improved so he trialed a clear liquid diet. In the morning he had a large bowel movement. Pain was gone. Tolerated a meal and is now ready to go home.  Flagyl was given to him as a just in case for diarrhea, at his request. Overall medically stable for discharge.  ED visit to hospital admission within 6 weeks of receiving the COVID vaccine.
Patient passed away unrelated to covid vaccine Narrative: The patient had Alzheimer dementia and acute on chronic renal failure. Patient received first dose of Pfizer vaccine on 1/13/2021 and second Pfizer vaccine on 2/2/2021. No adverse reaction was reported. Patient was recently admitted for LE edema and increasing SOB. Patient passed away on 3/8/2021 in hospital. No indication that death was related to COVID 19 vaccination.
1/4/2023 I had severe abdominal pain. I waited it out because I had to go to the bathroom a lot and did not feel like moving. I took diacylamine and used a heating pad. I have had this before, but this was more severe. The event lasted about four hours, but continued like someone punched me in the stomach for a couple of days.
Information has been received from a published literature article. Introduction: Hepatitis B virus (HBV) vaccination could produce a transiently detectable level of hepatitis B surface antigen (HBsAg), which might be misdiagnosed as prior exposure to HBV. This phenomenon was not widely recognized by gastroenterologists, leading to unnecessary testing. A 71-year-old male with end-stage renal disease on peritoneal dialysis was referred to the hepatology clinic for further investigation when routine evaluation for kidney transplant showed positive HBsAg. He received the Hepatitis B vaccine (manufacturer unknown) (lot #, dose, route not reported) 5 days prior to his positive blood test, He had history of blood transfusion in 1988, but no history of tattoos, Intravenous Drug User (IVDU), or other risk factors for acquiring  HBV infection. No previous history of liver disease, and his HBsAg was negative one year prior to his presentation to the reporter's clinic. He was asymptomatic and denied abdominal pain, jaundice, fever, change in urine or stool color, or nausea/vomiting. On examination, vital signs were stable with no other findings except the presence of left-sided abdominal wall peritoneal dialysis catheter in place. Initial blood tests (5 days post-vaccination) showed positive HBsAg, but HBcAb and HBsAb were negative. International normalised ration (INR), total bilirubin, Aspartate aminotransferase (AST), and Alanine aminotransferase (ALT) were within normal limits. Albumin was low; 2.9 (due to chronic kidney disease). Repeat testing for HBsAg, HBsAb, hepatitis BE antigen, and hepatitis B DNA (28 days post vaccination), all returned negative. The positive HBsAg could be a transient phenomenon related to recent Hepatitis B vaccine (manufacturer unknown) vaccination (usually within 14 days post vaccine). Caution should be exercised when interpreting HBsAg seropositivity within 4 weeks of HBV immunization. Our case highlighted the importance of clinical awareness of recent HBV vaccination as the cause of false positive HBsAg test. Additional information has been requested.
Breathing difficult; Parsonage-Turner Syndrome; cant workand is unable to use arms; numbness in left arm; sharp pain in  left arm; She can't work; This spontaneous case was reported by a patient and describes the occurrence of DYSPNOEA (Breathing difficult), HYPOAESTHESIA (numbness in left arm), MYALGIA (sharp pain in  left arm), NEURALGIC AMYOTROPHY (Parsonage-Turner Syndrome) and MOBILITY DECREASED (cant workand is unable to use arms) in a 45-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 027A21A and 031L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 05-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 10-Mar-2021, the patient experienced HYPOAESTHESIA (numbness in left arm) (seriousness criterion hospitalization) and MYALGIA (sharp pain in  left arm) (seriousness criterion hospitalization). On 09-Apr-2021, the patient experienced IMPAIRED WORK ABILITY (She can't work). On 29-Jun-2021, the patient experienced MOBILITY DECREASED (cant workand is unable to use arms) (seriousness criterion hospitalization). On an unknown date, the patient experienced DYSPNOEA (Breathing difficult) (seriousness criterion hospitalization) and NEURALGIC AMYOTROPHY (Parsonage-Turner Syndrome) (seriousness criterion hospitalization). At the time of the report, DYSPNOEA (Breathing difficult), HYPOAESTHESIA (numbness in left arm), MYALGIA (sharp pain in  left arm), NEURALGIC AMYOTROPHY (Parsonage-Turner Syndrome) and MOBILITY DECREASED (cant workand is unable to use arms) outcome was unknown and IMPAIRED WORK ABILITY (She can't work) had not resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter. Treatment information was not provided.  Company Comment : Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.  Further information has been requested-.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.  Further information has been requested-.
Polymyalgia rheumatica with pain in hip flexors, shoulders, upper back and neck
Severe pain at inj. site could not life my arm. Hard lumps, muscle and joint pain - had occupational therapy for two months before the pain began to subside.
Low fever (37,7° celsius), body pain, headacke and diarrhea appear 12 hours after vaccine and course for about 8 hours. After that, no more symptoms until now (35 hour from the vaccine).
Became very tired w/pain in lt arm @ inj site;also stiff neck & lt shoulder, Next day, had h/a, inc stiff neck,could not turn head side to side or tip head forward toward chest;problems standing erect, leaned to lt, trouble concentrating